Cardiome Pharma Corp. (CRME)

0.02 0.95
NASDAQ : Health Technology
Prev Close 2.10
Open 2.16
Day Low/High 2.08 / 2.17
52 Wk Low/High 1.29 / 4.84
Volume 35.32K
Avg Volume 163.40K
Exchange NASDAQ
Shares Outstanding 31.88M
Market Cap 81.99M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Window Dressing Could Arrive on Tuesday

However, if the market doesn't have a steady uptick in the morning, bulls who bought in anticipation of positive seasonality may give up.

Investigational BRINAVESS™ (vernakalant) For Infusion Recommended For Approval By The CHMP In The European Union (EU) For The Rapid Conversion Of Recent Onset Atrial Fibrillation

Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp.

(Graphic: Business Wire)

In a new Phase III study, BRINAVESS TM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) (NYSE: MRK) and Cardiome Pharma...

Two Guess Execs Sell $36.7M Worth

Maurice Marciano sells 577,500 shares and Paul Marciano sells 200,000.

Smart Modular, Cardiome: Early Volume Plays

Smart Modular, Cardiome: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Friday's session.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

AMAG: FDA Delays Feraheme Decision

AMAG: FDA Delays Feraheme Decision

AMAG says it expects the FDA to make its approval decision on iron replacement therapy Feraheme within a few days.

Biotech Stock Mailbag: HEB's Artful Dodging

Biotech Stock Mailbag: HEB's Artful Dodging

Readers chime in on Hemispherx, Genxyme, ASCO, Cell Therapeutics and Cardiome.

Cardiome Sees Improvement In Fourth Quarter

Despite falling revenue and a lack of license fees during the quarter, the drug company's net loss narrowed.

Health Winners & Losers: King Pharma

King Pharmaceuticals bucks an otherwise dismal day in health stocks.

Health Winners & Losers: Genentech

Drug company says "no" to Roche's advances, says make a better offer worth considering.

Health Winners & Losers: Altus

Shares of the company drop after announcing late-stage trial results that disappoint the Street.

Cardiome Sinks on FDA Info Request (Update)

The agency needs more info on irregular heart rhythm treatment vernakalant before it can consider approval.

Health Winners & Losers: King Pharma

King Pharma was among the health care-related stocks edging higher.

Cramer's 'Mad Money' Recap for July 23

GE's deal with a Middle East sovereign wealth fund will lift the company's shares, Cramer says.

'Mad Money Lightning Round': Lukewarm on TiVo

Cramer says the stock is OK and would buy it when it reaches $5.

Health Winners & Losers: St. Jude

St. Jude climbs on raised guidance.

Health Winners & Losers: Sequenom

Sequenom trades higher on an analyst upgrade.

Cardiome Climbs on Vernakalant Data

Cardiome Climbs on Vernakalant Data

It will move ahead with a phase III study of oral vernakalant using the 500-mg dose.

A Quiet Medicines Co. Raises Questions

The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.

Feuerstein's Biotech-Stock Mailbag

Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.

FDA Backlog Leaves Biotech Stocks in Limbo

A lack of resources leads the agency to push back drug approval deadlines, adding murkiness to an already tricky sector.

Monday's Winners & Losers: Bear Stearns

The brokerage loses 84% after a $2-a-share buyout offer.

Monday's Health Winners & Losers

Biotech indices are sinking, but Cardiome and QLT surge.

Biotech Notebook: Onyx, Genentech, Cardiome

Onyx's increased spending is even more troubling than its failed Nexavar trial. Elsewhere, Genentech faces a key FDA decision.

Feuerstein's Biotech-Stock Mailbag

Cardiome's radio silence on a delayed FDA decison is leaving many readers frustrated.

Tuesday's Winners & Losers: Motorola

Shares sink 7.6% ahead of earnings.

Tuesday's Health Winners & Losers

Cardiome Pharma won't get FDA decision until January.

Feuerstein's Biotech-Stock Mailbag

FDA is unlikely to reverse its earlier decision on Provenge.

Cardiome Drug Gets Committee Nod

An FDA cardiovascular advisory committee recommends approval of IV Vernakalant.